Newsletter Subject

Cytarbine || April 21.23

From

investingbagholder.com

Email Address

troy.gibbs@email.investingbagholder.com

Sent On

Fri, Apr 21, 2023 10:29 AM

Email Preheader Text

The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers…

The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers… Dear Investor, Cytarbine. That's the name of the most popular drug doctors prescribed last year to fight leukemia. Problem is, Cytarbine is a "chemical drug" that was patented almost 60 years ago. Chemical drugs are like nuclear weapons. Drop them inside your body and everything gets destroyed. It's why people say, "the chemo will get you before the cancer does." It gets even worse... 75% of all cancer drugs sold by Big Pharma are old chemical drugs like Cytarbine. Well guess what? On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can "Cut & Paste" any disease from your body. It's like this tiny biotech invented the iPhone while Big Pharma is still selling flip phones. And our research proves that [anyone who gets in today could to see a 46,751% return (or more)!]( The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers, Pfizer, Sanofi, Novartis and Teva. Sanofi has their own new drug on the market. Pfizer last month bought Array Biopharma, which we recommended. That leaves Novartis, Teva and Bristol Meyers. We think Bristol Meyers is the most likely buyer because their new leukemia drug recently flunked out of FDA trials. A deal could happen any day. A takeover of the company could hand investors [gains of up to 31,250% in the next 90 days...]( But we would be ok if there wasn't a deal. That's because Investor's Business Daily estimates this is a $75 billion market. Yet right now, its stock price is just a tiny fraction of that size. [CLICK HERE to see how you can profit from this rare opportunity]( Sincerely, Josh Kaplan Editor-in-Chief, Behind the Markets You are receiving this email because you have expressed an interest in the Financial Education niche on one of our landing pages or sign-up forms. [Quit]( To not miss out on any of our emails, be sure to [whitelist us.]( [Privacy Policy]( | [Terms & Conditions]( | [Unsubscribe]( (c) 2023 Investing Bag Holder. All Rights Reserved. 600 3rd Ave, New York, NY 10016, USA

Marketing emails from investingbagholder.com

View More
Sent On

25/04/2023

Sent On

24/04/2023

Sent On

23/04/2023

Sent On

22/04/2023

Sent On

20/04/2023

Sent On

19/04/2023

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.